Market Research Logo

Pneumocystis Infection - Pipeline Review, H1 2016

Pneumocystis Infection - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Pneumocystis Infection - Pipeline Review, H1 2016’, provides an overview of the Pneumocystis Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pneumocystis Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pneumocystis Infection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pneumocystis Infection
  • The report reviews pipeline therapeutics for Pneumocystis Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pneumocystis Infection therapeutics and enlists all their major and minor projects
  • The report assesses Pneumocystis Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pneumocystis Infection
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pneumocystis Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pneumocystis Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pneumocystis Infection Overview
Therapeutics Development
Pipeline Products for Pneumocystis Infection - Overview
Pipeline Products for Pneumocystis Infection - Comparative Analysis
Pneumocystis Infection - Therapeutics under Development by Companies
Pneumocystis Infection - Therapeutics under Investigation by Universities/Institutes
Pneumocystis Infection - Pipeline Products Glance
Early Stage Products
Pneumocystis Infection - Products under Development by Companies
Pneumocystis Infection - Products under Investigation by Universities/Institutes
Pneumocystis Infection - Companies Involved in Therapeutics Development
BioDiem Ltd
Matinas BioPharma Holdings, Inc.
Pneumocystis Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
atovaquone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BDM-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumocystis pneumonia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pneumocystis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumocystis Infection - Recent Pipeline Updates
Pneumocystis Infection - Dormant Projects
Pneumocystis Infection - Discontinued Products
Pneumocystis Infection - Product Development Milestones
Featured News & Press Releases
May 10, 2013: BioDiem's BDM-I Progresses To Preclinical Animal Studies In NIH Research Program As Fungal Infection Treatment
Jun 04, 2012: MiniVax’s Pneumocystis Vaccine Candidate Induces Significant anti-Pneumocystis Antibody Responses and Reduced Fungal Load
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pneumocystis Infection, H1 2016
Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Pneumocystis Infection - Pipeline by BioDiem Ltd, H1 2016
Pneumocystis Infection - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pneumocystis Infection Therapeutics - Recent Pipeline Updates, H1 2016
Pneumocystis Infection - Dormant Projects, H1 2016
Pneumocystis Infection - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Pneumocystis Infection - Comparative Analysis, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products by Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report